Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases

Abstract: There is provided a slide cover for a slide fastener. A pair of second guide element passages are formed in a space among an upper plate, a lower plate, a pair of outer wall portions and a pair of inner wall portions to guide a pair of separated element rows into a first element guide passage of a slider. The upper plate, the lower plate and a connection post have a concave surface, which is recessed in a disengaging direction of the slider, in a surface facing toward an engaging direction of the slider. The pair of second guide element passages are configured so that tip ends of the pair of inner wall portions in the engaging direction are located at the same positions as or at a side of the engaging direction relative to tip ends of the pair of outer wall portions in the engaging direction.

Abstract: There is provided a slider cover of a slide fastener. An upper mounting plate includes: an upper plate to be arranged above an upper blade of a slider and formed with a through-hole penetrating therethrough; and an upper wall protruding downward from the upper plate. A lower mounting plate includes: a lower plate to be arranged below a lower blade of the slider; and a lower wall for surrounding front, right and left sides of an outer periphery of the lower blade and protruding upward from the lower plate. At least one of the upper and lower mounting plates includes a protrusion protruding from an inner peripheral surface of at least corresponding one of the upper and lower walls and configured to come in close contact with a part of an outer peripheral surface of at least corresponding one of the upper and lower blades.

Abstract: A compound represented by general formula (I) and having a quinoline skeleton has a strong Axl inhibitory activity, and therefore the compound can be an agent for treating Axl-related diseases, for example, cancer such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.

Abstract: There is provided a slide cover for a slide fastener. A pair of second guide element passages are formed in a space among an upper plate, a lower plate, a pair of outer wall portions and a pair of inner wall portions to guide a pair of separated element rows into a first element guide passage of a slider. The upper plate, the lower plate and a connection post have a concave surface, which is recessed in a disengaging direction of the slider, in a surface facing toward an engaging direction of the slider. The pair of second guide element passages are configured so that tip ends of the pair of inner wall portions in the engaging direction are located at the same positions as or at a side of the engaging direction relative to tip ends of the pair of outer wall portions in the engaging direction.

Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases

Abstract: A compound represented by the general formula (1) has a pyridone ring structure introduced into a pyrrolo pyrimidine skeleton, so that the compound has a strong Axl inhibitory activity. Consequently, the compound can be used as a therapeutic agent for Axl-related diseases including cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.

Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.

Abstract: A compound represented by the general formula (1) has a pyridone ring structure introduced into a pyrrolo pyrimidine skeleton, so that the compound has a strong Axl inhibitory activity. Consequently, the compound can be used as a therapeutic agent for Axl-related diseases including cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.

Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.

Abstract: For the prevention and/or treatment of chymase-mediated diseases such as skin diseases, circulatory diseases, digestive system diseases, respiratory diseases, liver diseases, ocular diseases or the like, a drug is provided having as an active ingredient a compound having extremely strong chymase inhibitory activity, high safety, and high metabolic stability. The compound represented by the formula (I): wherein all symbols have the same meanings as in the description, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof, is useful as a pharmaceutical ingredient having chymase inhibitory activity for preventing and/or treating of chymase-mediated disease, such as skin diseases, circulatory diseases, digestive system diseases, respiratory diseases, liver diseases, ocular diseases or the like.

Abstract: For the prevention and/or treatment of chymase-mediated diseases such as skin diseases, circulatory diseases, digestive system diseases, respiratory diseases, liver diseases, ocular diseases or the like, a drug is provided having as an active ingredient a compound having extremely strong chymase inhibitory activity, high safety, and high metabolic stability. The compound represented by the formula (I): wherein all symbols have the same meanings as in the description, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof, is useful as a pharmaceutical ingredient having chymase inhibitory activity for preventing and/or treating of chymase-mediated disease, such as skin diseases, circulatory diseases, digestive system diseases, respiratory diseases, liver diseases, ocular diseases or the like.